ABSTRACT
Since gamma-glutamyl transpeptidase (GGT) is highly and locally expressed in human breast cancer, a GGT-enzymatically activatable fluorescent probe, gamma-glutamyl hydroxymethyl rhodamine green (gGlu-HMRG), has been developed to detect the human breast cancer area with high performance. In this study, GGT expression and the efficacy of gGlu-HMRG on visualization were investigated in canine mammary gland tumors (MGT). Seventeen non-fixed fresh-frozen MGT specimens and each peritumoral control tissue were utilized. The GGT mRNA levels were highly observed in the tumor specimens compared with the control. GGT immunostaining was mostly observed on the cell membrane and cytosol of the alveolar and duct mammary epithelium of MGT tissues. These signals were strongly positive in several cases while they were mild to not observed in other cases. When gGlu-HMRG solution was dropped to the non-fixed tissue pieces of MGT or control tissues, the fluorescence intensities (FIs) were measured using Maestro in-vivo imaging device. FIs in MGT tissues were significantly higher than each control tissue 20 min after treatment. Based on Youden index method, the maximum sensitivity and specificity of FI was 82.4% and 82.4%. These findings suggest that GGT is highly expressed in several MGTs in dogs and gGlu-HMRG could visualize at least a part of MGT tissues in dogs. Nevertheless, it should be needed to assess the false-negative areas more carefully in canine than human cases.
Subject(s)
Dog Diseases , Mammary Neoplasms, Animal , Animals , Dog Diseases/diagnostic imaging , Dogs , Female , Fluorescent Dyes/metabolism , Mammary Neoplasms, Animal/diagnostic imaging , Rhodamines/metabolism , gamma-GlutamyltransferaseABSTRACT
Chronopharmacology is the study of the varying responses of drugs to changes in biological timing and endogenous periodicities. The dipeptidyl peptidase-4 inhibitor sitagliptin is a globally prescribed anti-hyperglycemic drug. Although dipeptidyl peptidase-4 inhibitors are usually administered once, the specific intake time is generally not mentioned. Therefore, this study aimed at investigating the diurnal effects of sitagliptin-induced anti-hyperglycemia in high-fat diet (HFD)-induced obesity in mice. Five-week-old male C57BL/6J mice were fed normal (control) diet or HFD for 10 weeks. During the last 2 weeks, the mice were administered saline or sitagliptin (10 mg/kg, per os) in the light or dark phase, respectively. At the end of the experiment, the mice were euthanized after an 18 h fasting period, and plasma and tissue samples (liver, kidney, and epididymal white adipose tissues) were collected, or the oral glucose tolerance test was performed. Sitagliptin administration in the light phase significantly decreased plasma glucose levels, insulin levels, hepatic steatosis, and restored the glucose tolerance compared with the HFD group. In contrast, these parameters remained unchanged in the dark phase-treated mice. Our data therefore suggests that sitagliptin portrays definite chronopharmacology, which may provide valuable information on the importance of drug administration timing for maximum pharmacological effects.
Subject(s)
Drug Chronotherapy , Hyperglycemia/prevention & control , Hypoglycemic Agents/administration & dosage , Obesity/drug therapy , Sitagliptin Phosphate/administration & dosage , Adipose Tissue/drug effects , Adipose Tissue/metabolism , Adipose Tissue/pathology , Animals , Blood Glucose/analysis , Diet, High-Fat , Disease Models, Animal , Glucose/metabolism , Hyperglycemia/metabolism , Hypoglycemic Agents/therapeutic use , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Mice, Inbred C57BL , Obesity/blood , Organ Size/drug effects , Sitagliptin Phosphate/therapeutic useABSTRACT
Chronopharmacology is the study of the varying responses of drugs to changes in biological timing and endogenous periodicities. The selective sodium-glucose cotransporter 2 inhibitor, dapagliflozin, is a globally prescribed antihyperglycemic drug. Although dapagliflozin is usually administered once a day, the specific intake time is generally not mentioned. Therefore, this study aimed at investigating the diurnal effects of dapagliflozin on high-fat diet (HFD)-induced obesity in mice. Five-week-old male C57BL/6J mice were fed a normal (control) diet or HFD for 10 weeks. During the last 2 weeks, the mice were administered olive oil/ethanol emulsion or dapagliflozin (1mg/kg, p.o.) in the light or dark phase. At the end of the experiment, the mice were euthanized after an 18h fasting period, and plasma and tissue samples (epididymal white adipose tissues, liver, and kidney) were collected. Dapagliflozin administration in the light phase significantly decreased plasma glucose levels, insulin levels, adipose adipokines, and decreased the size of adipocytes, compared with the HFD group. In contrast, these parameters remained unchanged in the mice treated during the dark phase. Our data therefore suggests that dapagliflozin portrays definite chronopharmacology, which may provide valuable information on the importance of drug administration timing for maximal pharmacological effects.
Subject(s)
Benzhydryl Compounds/pharmacology , Circadian Rhythm/physiology , Glucosides/pharmacology , Hypoglycemic Agents/pharmacology , Adipocytes/drug effects , Adipocytes/metabolism , Adipokines/biosynthesis , Animals , Blood Glucose/analysis , Body Weight/drug effects , Diet, High-Fat , Male , Mice , Mice, Inbred C57BL , Sodium-Glucose Transporter 2 Inhibitors/pharmacologyABSTRACT
Nanosecond-scale pulsed laser irradiation of cis,cis-1,3-cyclooctadiene via an Nd:YAG laser at 266 nm induced highly selective cyclization of the 1,3-diene moiety to afford cis-bicyclo[4.2.0]oct-7-ene in high yield. The pulsed Nd:YAG laser light is highly monochromatic thereby allowing efficient control of the photoreaction selectivity by controlling the photostationary state.
